It is reported that D3 Bio, a developer of oncology therapeutics, is planning a listing in Hong Kong with a target to raise $200 million and is currently in discussions with investment banks regarding the matter. D3 Bio has developed a new generation of cancer drugs, with preliminary evidence showing significant inhibition of solid tumors triggered by specific genetic mutations, including non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Information shows that D3 Bio completed a $108 million Series B financing round in December last year, with participation from IDG Capital and Songqing Capital, while existing investors including WuXi AppTec's venture fund, Temasek, Sequoia China, Matrix Partners, and Medicxi continued to add to their investments. It is understood that Boyu Capital is also one of the shareholders. The proceeds from D3 Bio's Series B financing are intended to support the global Phase III pivotal clinical study of its core drug candidate, elisrasib (D3S-001), evaluating its use both as a monotherapy and in combination for patients with KRAS G12C mutant tumors, covering regions including the United States, China, and the European Union, to advance global registration applications.